Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential two-dose booster study of Omicron inactivated COVID-19 vaccines versus prototype inactivated vaccine in previously vaccinated adults
ChiCTR2200060544Phase 3Not yet recruiting
- Sponsor
- The University of Hong Kong
- Start
- Apr 2022
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of BBIBP-CorV, inactivated SARS-CoV-2 vaccine (WIBP) and turkovac in coronavirus disease 2019 (COVID-19) (6 arms), sponsored by The University of Hong Kong. Primary endpoints: GMT and 4-fold rise rate of anti-Omicron neutralizing antibody, Incidence of adverse reactions/events and 1 more. Planned start Apr 2022; status: not yet recruiting.
02
Drugs
BBIBP-CorVinactivated SARS-CoV-2 vaccine (WIBP)turkovac
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2200060544.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200060544.